Alnylam Pharmaceuticals has named Judy Lieberman, a senior investigator at the CBR Institute for Biomedical Research and a professor at Harvard Medical School, to its scientific advisory board.

The appointment comes a little more than a month after Alnylam licensed delivery technology developed by Lieberman from Harvard.

Lieberman holds a PhD in physics from Rockefeller University and an MD from the joint Harvard-Massachusetts Institute of Technology program in health, science, and technology.